Postprocedure administration of insulin in canine autologous vein grafting: a potential strategy to attenuate intimal hyperplasia.
Intimal hyperplasia (IH) exerts a critical role in vein graft failure after arterial bypassing. Insulin has been demonstrated to remarkably decrease IH in the rat carotid injury model. We hypothesized that postoperative insulin medication prevents the autologous vein graft from IH. Dogs were subjected to jugular-carotid interposition bypass grafting and intravenously infused with vehicle, glucose-insulin-potassium, glucose-potassium, or glucose-insulin-potassium plus Wortmannin 5 minutes before and 4 hours after reperfusion. Then vein grafts were harvested for caspase-3 activation, cell apoptosis, phosphorylated Akt, and endothelial nitric oxide synthase level assays. Other dogs undergoing the same operation were administered with subcutaneous injection of 4 U insulin or 0.5 mL saline two times per day for 1 month postoperatively. Vein grafts were sampled to assess cell proliferation, intimal/medial thickness, and expression of endothelial nitric oxide synthase and [alpha]-smooth muscle actin. Glucose-potassium aggravated apoptosis and caspase-3 activation and decreased Akt and endothelial nitric oxide synthase phosphorylation; however, glucose-insulin-potassium significantly inhibited cell apoptosis and caspase-3 activation and increased phosphorylated Akt and pendothelial nitric oxide synthase levels in canine vein grafts. Wortmannin largely abolished the glucose-insulin-potassium-elicited effects. Moreover, postoperative insulin use greatly inhibited cell proliferation, reduced intimal/medial thickness, upregulated endothelial nitric oxide synthase, and [alpha]-smooth muscle actin expression. Insulin protects autologous vein grafts possibly through the phosphatidylinositol-3 kinase/Akt signaling pathway and prevents IH in autologous vein grafts.
Zhou
Ning
N
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Yu
Qiu-Jun
QJ
Si
Rui
R
Gao
Hao-Kao
HK
Wang
Ting
T
Gao
Feng
F
Wang
Hai-Chang
HC
Bian
Jie-Fang
JF
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D017536:Carotid Artery, Common / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D053148:Caspase 3 / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004285:Dogs; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D006085:Graft Survival; D006965:Hyperplasia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007601:Jugular Veins / Q000187:drug effects* / Q000473:pathology / Q000637:transplantation; D008297:Male; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000473:pathology; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010766:Phosphorylation; D011184:Postoperative Period; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D014182:Transplantation, Autologous; D017539:Tunica Intima / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D058017:Vascular Grafting
D007004:Hypoglycemic Agents; D007328:Insulin; D052250:Nitric Oxide Synthase Type III; D051057:Proto-Oncogene Proteins c-akt; D053148:Caspase 3